Korro Bio, Inc. — Form SCHEDULE 13D/A
Filed August 4, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Two reporting persons, Atlas XI and AVOF II, conducted multiple sales of Korro Bio common stock between May 28 and July 6, 2026. Total shares sold: Atlas XI ~235,517 shares; AVOF II ~48,370 shares at weighted average prices ranging from $13.95–$14.98 per share. These sales represent approximately 0.32–0.53% of current market value (~$89M), distributed across six separate tranches.
Why this rating
Routine insider/affiliate liquidation; modest relative to $89M company scale; no control change or strategic impact signaled.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.